Head-to-head · WeighScore
Genesis Health vs NuuVim
The verdict
Too close to call — both grade 68.2/100 (C).
Genesis Health and NuuVim land on the same WeighScore, so neither clears the other on our six graded dimensions. Genesis Health sits one line higher on the board (#150 vs #153) on the underlying tiebreak, but it's a genuine coin-flip — pick on the factors and prices that matter most to you below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Genesis Health | NuuVim |
|---|---|---|
| WeighScore | 68.2/100 | 68.2/100 |
| Grade | C | C |
| Scorecard rank | #150 | #153 |
| Semaglutide | $175/mo (starting dose, compounded) | $79/mo (all doses, 3-mo plan, new patients only, compounded) |
| Tirzepatide | $235/mo (starting dose, compounded) | $133/mo (all doses, 3-mo plan, new patients only, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #150 · C
Strengths
- Annual plan as low as $99/mo for semaglutide or $125/mo for tirzepatide
- Offers both compounded and brand-name GLP-1s (Wegovy, Ozempic, Zepbound) in one platform
- Includes health coaching, active community, and free expedited shipping on every plan
- LegitScript certified; medications sourced from audited, licensed US compounding pharmacies
- Same-day provider visits, personalized dosing, and 24/7 care team messaging
Where it loses points
- States served not publicly listed; telehealth coverage unconfirmed for all states
- Monthly starting price ($175 sema / $235 tirz) is mid-market without annual commitment
- Labs not disclosed or included in any published plan tier
- Brand-name GLP-1 pricing not published; insurance or coupon required
- Compounded medications are not FDA-approved
Graded #153 · C
Strengths
- Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
- Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
- LegitScript Certified and HIPAA-compliant
- Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
- Operating legal entity disclosed: NuuVim LLC, Texas governing law
Where it loses points
- There is no month-to-month plan: every rate is billed as one three-month payment
- The advertised $79 and $133 are introductory rates for customers new to GLP-1s; on renewal they become $133 and $199.67
- The site's own llms.txt advertises pricing, FAQ and terms files that all 404
- No state count is published
- FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.